[Event Report] FY2023 AMR Alliance Japan Planning Meeting (February 2, 2023)
date : 3/9/2023
Tags: AMR
![[Event Report] FY2023 AMR Alliance Japan Planning Meeting (February 2, 2023)](https://hgpi.org/en/wp-content/uploads/sites/2/AMRalliance-logo-11-29.jpg)
AMR Alliance Japan (Secretariat: Health and Global Policy Institute) held a meeting to discuss its FY2023 plans among Alliance members.
AMR Alliance Japan, as an independent platform for multisector discussion with the mission of contributing to the improvement of public health by promoting measures on AMR, will continue to work with Alliance members and partner organizations to deepen policy debate around AMR.
■Overview
Date and time: Thursday, February 2, 2023
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Discussion
Participants (Titles omitted; in no particular order)
Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Hiroshi Itoh (Internal Medicine, Medical Affairs, Pfizer Japan Inc.)
Rie Ueno (BioMérieux Japan Ltd, Director Medical Affairs)
Kazunobu Ouchi (President, Japanese Society for Pediatric Infectious Diseases / Specially Appointed Professor, Department of Medical Welfare for Children, Faculty of Health and Welfare, Kawasaki University of Medical Welfare / Specially Appointed Manager, Kawasaki Medical School General Medical Center / Professor emeritus, Kawasaki Medical School)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Katsunori Kanazawa (Officer Infectious Diseases, Medical Information, Sumitomo Pharma Co., Ltd.)
Satoshi Kamayachi (Executive Board Member, Japan Medical Association)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
Hayato Shishido (Manager, Business Development Department, Research & Development Division, NISSUI PHARMACEUTICAL CO., LTD)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Mitsuru Sugawara (President, Japanese Society of Therapeutic Drug Monitoring / Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
Yoshisaburo Takahashi (General Manager, Vaccine/Infections Dept., Meiji Seika Pharma Co., Ltd.)
Hiroshi Taki (Manager, Policy & Public Affairs, Pfizer Japan Inc.)
Kazuhiro Tateda (Chairman, the Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, AMR Incentives and Advocacy TF, Japan Pharmaceutical Manufacturers Association)
Mitsuaki Nagasawa (Vice-president, Japanese Association of Medical Technologists)
Testuya Matsumoto (President, Japanese Society of Chemotherapy / President, Japanese society for clinical microbiology / Chief Professor, Department of Infectious Diseases, International University of Health and Welfare Graduate School of Medicine)
Megumi Maruyama (Global Health Officer, Sumitomo Pharma Co., Ltd.)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akira Yuasa (Senior Manager, HTA/HEOR, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control)
Hiroshi Yotsuyanagi (President, Japanese Association for Infectious Diseases / Director, IMUST Hospital, Institute of Medical Science, University of Tokyo)
Moderator:
Yui Kohno (Manager, Health and Global Policy Institute)
Top Research & Recommendations Posts
- [Policy Recommendation] Preparing for “Disaster-Level Heat” in the 2025 Basic Policy on Economic and Fiscal Management and Reform (June 9, 2025)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Event Report] Round Table Discussion “Understanding Menopausal Women’s Health as a Social Issue” (November 19, 2024)
- [Policy Recommendation] Integrating “Planetary Health” as a Growth Strategy — Proposal for the Grand Design and Action Plan for a New Form of Capitalism (2025 Revised Edition) (June 9, 2025)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
- [Policy Recommendations] HGPI Joint Input to the Zero Draft Political Declaration on NCDs and Mental Health (May 23, 2025)
Featured Posts
-
2025-07-04
[Registration Open] (Webinar) The 136th HGPI Seminar “Where We Are Now and Where We Are Going Regarding PPI in Mental Health Research: Learning from the TOGETHER Project in the Form of Co-Creation” (July 28, 2025)
-
2025-07-04
[Event Report] The HGPI Cardiovascular Disease (CVD) Control Promotion Project Online Global Symposium “Exploring the Future of CVD Control Through Policy Case Studies in the Asia-Pacific Region” (March 13, 2025)
-
2025-07-04
[HGPI Policy Column] (No. 62) From the Dementia Project “The Current State of Dementia Policy in the International Community in 2025”
-
2025-07-04
[Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
-
2025-07-08
[Registration Open] Planetary Health Academy (Starts August 2025)